Search Results - "Brecht, J G"

Health-economic comparison of three recommended drugs for the treatment of osteoporosis by Brecht, J G, Kruse, H P, Möhrke, W, Oestreich, A, Huppertz, E

“…Osteoporosis is a large and growing disease with significant health consequences. Based on an evaluation of clinical evidence, the German osteology umbrella…”
Get more information

Pharmacoeconomic analysis of osteoporosis treatment with risedronate by Brecht, J G, Kruse, H P, Felsenberg, D, Möhrke, W, Oestreich, A, Huppertz, E

“…Hip fracture is an important and costly problem. Therapy with the bisphosphonate risedronate effectively prevents hip and other fractures among women with…”
Get more information

Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study by Schulze-Koops, H, Deeg, M, Runge, C, Volmer, T, Brecht, J G

“…The TEMPO study has shown that the combination of etanercept and methotrexat (MTX) in the treatment of rheumatoid arthritis (RA) is superior to monotherapy. It…”
Get full text

Burden of Illness Imposed by Osteoporosis in Germany by Brecht, J. G., Schädlich, P. K.

“…In the course of aging, especially in women after menopause, osteoporosis leads to loss of bone mass, with a considerable increase in the risk of fracture over…”
Get full text

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany by Schädlich, P K, Brecht, J G

“…To use published data to compare the economic consequences of specific immunotherapy (SIT) lasting 3 years with those of continuous symptomatic treatment in…”
Get full text

A graphic method of estimating the specificity of screening programmes from incomplete follow-up data by Brecht, J G, Robra, B P

Get more information

The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study by Schädlich, P K, Brecht, J G

“…Alcoholism places a considerable economic burden on society. The rate of relapse of previously weaned alcoholics has been shown to decrease following treatment…”
Get full text

Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective by Aurbach, A, Russ, W, Brecht, JG, Schdlich, PK

Get full text

Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance by Schädlich, P K, Brecht, J G, Brunetti, M, Pagano, E, Rangoonwala, B, Huppertz, E

“…In the Ramipril Efficacy In Nephropathy (REIN) trial, ramipril significantly lowered the rate of reaching the combined end-point of doubling of baseline serum…”
Get full text

Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance by Schädlich, P K, Huppertz, E, Brecht, J G

“…Data from the Acute Infarction Ramipril Efficacy (AIRE) study were used in a cost-effectiveness analysis to determine the incremental cost per life-year gained…”
Get full text

Evaluation of German cancer screening by cross-sectional data by Schwartz, F W, Brecht, J G

“…Annual cervical cancer screening in the Federal Republic of Germany (FRG) has been free for about 93% of the female population over 29 years old since 1971…”
Get more information

Alcoholism. The cost of illness in the Federal Republic of Germany by Brecht, J G, Poldrugo, F, Schädlich, P K

“…The purpose of this study was to estimate the direct and indirect costs of alcoholism in the Federal Republic of Germany. Direct costs comprised treatment…”
Get full text

Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany by Schädlich, P K, Paschen, B, Brecht, J G

“…The Cardiac Insufficiency Bisoprolol Study (CIBIS) demonstrates that, for patients with heart failure of different aetiologies, administration of the beta…”
Get full text

Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany by Schädlich, P K, Zeidler, H, Zink, A, Gromnica-Ihle, E, Schneider, M, Straub, C, Brecht, J G, Huppertz, E

“…Since November 1999, leflunomide (LEF), an innovative disease-modifying antirheumatic drug (DMARD), is available in Germany for treatment of rheumatoid…”
Get full text

Gesundheitsökonomische Bewertung der Kombinationstherapie der rheumatoiden Arthritis mit Methotrexat und Etanercept auf der Basis der TEMPO-Studie by Schulze-Koops, H., Deeg, M., Runge, C., Volmer, T., Brecht, J.G.

“…Zusammenfassung Hintergrund Die TEMPO-Studie hat die Überlegenheit der Kombination von Etanercept und Methotrexat (MTX) bei der Behandlung der rheumatoiden…”
Get full text

ES3 PROCESS OPTIMIZATION IN A 10-BED INTENSIVE CARE UNIT (ICU) IN GERMANY: IMPACT ON CASE-RELATED TREATMENT COSTS by Brecht, JG, Mueller, K, Welte, R, Schädlich, P

Get full text

Wirtschaftlichkeit von Leflunomid bei sequentieller Basistherapie der rheumatoiden Arthritis in Deutschland by Sch dlich, P. K., Zeidler, H., Zink, A., Gromnica-Ihle, E., Schneider, M., Straub, C., Brecht, J. G., Huppertz, E.

Get full text

Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany by Schädlich, P K, Paschen, B, Brecht, J G

“…The Cardiac Insufficiency Bisoprolol Study (CIBIS) demonstrates that, for patients with heart failure of different etiologies, the administration of the…”
Get more information

PCV37 ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY by Schadlich, PK, Lehmacher, W, Huppertz, E, Grewe, R, Brecht, JG

Get full text

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany. II. The contribution of leflunomide to efficiency by SCHÄDLICH, Peter K, ZEIDLER, Henning, ZINK, Angela, GROMNICA-IHLE, Erika, SCHNEIDER, Matthias, STRAUB, Christoph, BRECHT, Josef G, HUPPERTZ, Eduard

“…To estimate the 3-year incremental cost effectiveness and cost utility of introducing leflunomide into sequential therapy, consisting of the most frequently…”
Get full text